公开(公告)号：US20240052354A1

公开(公告)日：2024-02-15

申请号：US18048015

申请日：2022-10-19

Applicant: NOVARTIS AG

Inventor： Eric BILLY ,  Antoine DE WECK ,  Javad GOLJI ,  Gregory HOFFMAN ,  Francesco HOFMANN ,  Audrey KAUFFMANN ,  Konstantinos John MAVRAKIS ,  Earl Robert MCDONALD, III ,  William SELLERS ,  Tobias SCHMELZLE ,  Frank Peter STEGMEIER ,  Michael Ray SCHLABACH, JR.

IPC: C12N15/115 ,  A61K45/06 ,  C12N9/22 ,  C12N15/113 ,  G01N33/574 ,  A61K47/18

CPC classification number: C12N15/115 ,  A61K45/06 ,  C12N9/22 ,  C12N15/113 ,  G01N33/574 ,  A61K47/18 ,  C12N2310/20 ,  C12N2310/14 ,  G01N2800/52

Abstract: The disclosure provides novel personalized therapies, kits, transmittable forms of information and methods for use in treating patients having cancer, wherein the cancer is amenable to therapeutic treatment with an inhibitor, e.g., an inhibitor of any of the targets disclosed herein. Kits, methods of screening for candidate inhibitors, and associated methods of treatment are also provided.

公开(公告)号：US20240382600A1

公开(公告)日：2024-11-21

申请号：US18687615

申请日：2022-08-30

Applicant: Novartis AG

Inventor： Emilie CHAPEAU ,  Patrick CHENE ,  Pascal FURET ,  Laurence KIEFFER ,  Rainer MACHAUER ,  Anne PICARD ,  Tobias SCHMELZLE ,  Holger SELLNER ,  Nicolas SOLDERMANN ,  Markus VOEGTLE ,  Markus WARTMANN

IPC: A61K47/54 ,  A61K47/55 ,  C07D405/14 ,  C07D417/12

Abstract: The present disclosure relates to a conjugate comprising a YAP/TAZ-TEAD Protein Protein Interaction Inhibitor (PPII) linked to a Ligase Binder via a linker, or a pharmaceutically acceptable salt thereof, as well as methods of using such conjugates.

公开(公告)号：US20250101435A1

公开(公告)日：2025-03-27

申请号：US18664977

申请日：2024-05-15

Applicant: Novartis AG

Inventor： Eric BILLY ,  Antoine DE WECK ,  Javad GOLJI ,  Gregory HOFFMAN ,  Francesco HOFMANN ,  Audrey KAUFFMANN ,  Konstantinos John MAVRAKIS ,  Earl Robert MCDONALD, III ,  William SELLERS ,  Tobias SCHMELZLE ,  Frank Peter STEGMEIER ,  Michael Ray SCHLABACH, Jr.

IPC: C12N15/115 ,  A61K45/06 ,  A61K47/18 ,  C12N9/22 ,  C12N15/113 ,  G01N33/574

Abstract: The disclosure provides novel personalized therapies, kits, transmittable forms of information and methods for use in treating patients having cancer, wherein the cancer is amenable to therapeutic treatment with an inhibitor, e.g., an inhibitor of any of the targets disclosed herein. Kits, methods of screening for candidate inhibitors, and associated methods of treatment are also provided.

公开(公告)号：US20240382457A1

公开(公告)日：2024-11-21

申请号：US18776928

申请日：2024-07-18

Applicant: Novartis AG

Inventor： Vincent BORDAS ,  Cara BROCKLEHURST ,  Patrick CHENE ,  Pascal FURET ,  Vito GUAGNANO ,  Patricia IMBACH-WEESE ,  Joerg KALLEN ,  Mickael LE DOUGET ,  Edwige Liliane Jeanne LORTHIOIS ,  Joseph MCKENNA ,  Bahaa SALEM ,  Tobias SCHMELZLE ,  Holger SELLNER ,  Nicolas SOLDERMANN ,  Markus VOEGTLE ,  Markus WARTMANN

IPC: A61K31/4155 ,  A61K31/343 ,  A61K31/351 ,  A61K31/357 ,  A61K31/4025 ,  A61K31/403 ,  A61K31/41 ,  A61K31/426 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/4525 ,  A61K31/506 ,  A61P35/00 ,  C07D307/81 ,  C07D405/04 ,  C07D405/12 ,  C07D405/14 ,  C07D407/04 ,  C07D407/12 ,  C07D417/04

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.

公开(公告)号：US20210155932A1

公开(公告)日：2021-05-27

申请号：US16632777

申请日：2018-07-20

Applicant: NOVARTIS AG

Inventor： Eric BILLY ,  Antoine DEWECK ,  Javad GOLJI ,  Gregory HOFFMAN ,  Francesco HOFMANN ,  Audrey KAUFFMANN ,  Konstantinos John MAVRAKIS ,  Earl Robert MCDONALD, III ,  William SELLERS ,  Tobias SCHMELZLE ,  Frank Peter STEGMEIER ,  Michael Ray SCHLABACH, Jr.

IPC: C12N15/115 ,  C12N15/113 ,  C12N9/22 ,  A61K45/06 ,  G01N33/574

Abstract: The disclosure provides novel personalized therapies, kits, transmittable forms of information and methods for use in treating patients having cancer, wherein the cancer is amenable to therapeutic treatment with an inhibitor, e.g., an inhibitor of any of the targets disclosed herein. Kits, methods of screening for candidate inhibitors, and associated methods of treatment are also provided.

公开(公告)号：US20240374571A1

公开(公告)日：2024-11-14

申请号：US18687616

申请日：2022-08-30

Applicant: Novartis AG

Inventor： Emilie CHAPEAU ,  Laurent L'EPICIER-SANSREGRET ,  Tobias SCHMELZLE

IPC: A61K31/416 ,  A61K31/4439 ,  A61K31/497 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/55 ,  A61P35/00

Abstract: The invention relates to a pharmaceutical combination comprising a TEAD inhibitor in combination with a first and optionally a second therapeutically active agent. The present invention also relates to methods of treating cancer involving administering to a subject in need thereof the TEAD inhibitor in combination with the first and optionally the second therapeutically active agent.

公开(公告)号：US20210299100A1

公开(公告)日：2021-09-30

申请号：US17201268

申请日：2021-03-15

Applicant: Novartis AG

Inventor： Vincent BORDAS ,  Cara BROCKLEHURST ,  Patrick CHENE ,  Zhongbo FEI ,  Pascal FURET ,  Vito GUAGNANO ,  Patricia IMBACH-WEESE ,  Joerg KALLEN ,  Mickael LE DOUGET ,  Jialiang LI ,  Wei LI ,  Edwige Liliane Jeanne LORTHIOIS ,  Joseph McKENNA ,  Bahaa SALEM ,  Tobias SCHMELZLE ,  Holger SELLNER ,  Nicolas SOLDERMANN ,  Markus VOEGTLE ,  Markus WARTMANN

IPC: A61K31/4155 ,  C07D307/81 ,  C07D405/12 ,  A61K31/343 ,  A61K31/443 ,  A61K31/426 ,  C07D417/04 ,  C07D407/04 ,  A61K31/357 ,  C07D405/04 ,  A61K31/403 ,  A61K31/4525 ,  A61K31/351 ,  C07D407/12 ,  A61K31/506 ,  A61K31/41 ,  A61K31/4025 ,  A61K31/4439 ,  C07D405/14 ,  A61P35/00

Abstract: The present invention provides a compound of formula (1) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.